Swift Biosciences Launches Normalase Amplicon Panel (SNAP) SARS-CoV-2 Kit
By HospiMedica International staff writers Posted on 29 May 2020 |
Image: Swift Normalase Amplicon Panel (SNAP) SARS-CoV-2 kit (Photo courtesy of Swift Biosciences, Inc.)
Swift Biosciences, Inc. (Ann Arbor, MI, USA), which focuses on commercialization of DNA and RNA library preparation kits for Next-Generation Sequencing (NGS), has released its Swift Normalase Amplicon Panel (SNAP) SARS-CoV-2 kit.
Targeting the full viral genome in a single tube reaction with a rapid two-hour workflow, Swift's assay enables research and surveillance activities by accommodating the low viral copy titers found in clinical specimens. The two-round PCR kit supports high throughput processing by converting and enriching viral cDNA into multiplexed, NGS-ready libraries.
Unlike competing amplicon enrichment workflows that require subsequent NGS library construction, Swift's NGS assay is a straight two-round amplicon PCR that adds adapters directly without a secondary library construction. It works with samples that fail other methods with high qRT-PCR Ct values, while providing complete genome coverage.
Swift's new SNAP workflow offers Illumina-compatible index combinations for processing up to 384 samples per sequencing run and generate libraries that are flexible to conventional library quantification methods, as well as Swift Normalase to support increased throughput and scalability.
"Our new SNAP technology leverages Swift's patented multiplex PCR approach to target and amplify the entire 30 kb viral genome in a single tube reaction, which maximizes genome coverage and yields from as few as 10 viral copies," said Drew McUsic, PhD, Swift's Director of Product Management. "Our collaborators at NYU and University of Washington have demonstrated high sensitivity and the ability to track viral mutations with an NGS workflow that doesn't substantially increase time or labor demands compared to qRT-PCR."
Related Links:
Swift Biosciences, Inc.
Targeting the full viral genome in a single tube reaction with a rapid two-hour workflow, Swift's assay enables research and surveillance activities by accommodating the low viral copy titers found in clinical specimens. The two-round PCR kit supports high throughput processing by converting and enriching viral cDNA into multiplexed, NGS-ready libraries.
Unlike competing amplicon enrichment workflows that require subsequent NGS library construction, Swift's NGS assay is a straight two-round amplicon PCR that adds adapters directly without a secondary library construction. It works with samples that fail other methods with high qRT-PCR Ct values, while providing complete genome coverage.
Swift's new SNAP workflow offers Illumina-compatible index combinations for processing up to 384 samples per sequencing run and generate libraries that are flexible to conventional library quantification methods, as well as Swift Normalase to support increased throughput and scalability.
"Our new SNAP technology leverages Swift's patented multiplex PCR approach to target and amplify the entire 30 kb viral genome in a single tube reaction, which maximizes genome coverage and yields from as few as 10 viral copies," said Drew McUsic, PhD, Swift's Director of Product Management. "Our collaborators at NYU and University of Washington have demonstrated high sensitivity and the ability to track viral mutations with an NGS workflow that doesn't substantially increase time or labor demands compared to qRT-PCR."
Related Links:
Swift Biosciences, Inc.
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans